276 related articles for article (PubMed ID: 30835635)
1.
Hagiya H; Aoki K; Akeda Y; Yamamoto N; Shanmugakani RK; Ishii Y; Tomono K
Microb Drug Resist; 2019; 25(6):839-845. PubMed ID: 30835635
[No Abstract] [Full Text] [Related]
2. In Vitro Efficacy of Meropenem-Cefmetazole Combination Therapy against New Delhi Metallo-β-lactamase-producing Enterobacteriaceae.
Hagiya H; Sugawara Y; Tsutsumi Y; Akeda Y; Yamamoto N; Sakamoto N; Shanmugakani RK; Abe R; Takeuchi D; Nishi I; Ishii Y; Hamada S; Tomono K
Int J Antimicrob Agents; 2020 Mar; 55(3):105905. PubMed ID: 31991221
[TBL] [Abstract][Full Text] [Related]
3. Bactericidal efficacy of meropenem in combination with cefmetazole against IMP-producing carbapenem-resistant Enterobacteriaceae.
Abe R; Hagiya H; Akeda Y; Yamamoto N; Ishii Y; Tomono K
BMC Res Notes; 2019 Nov; 12(1):740. PubMed ID: 31706328
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.
Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H
Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129
[TBL] [Abstract][Full Text] [Related]
6. Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC.
Barnes MD; Taracila MA; Good CE; Bajaksouzian S; Rojas LJ; van Duin D; Kreiswirth BN; Jacobs MR; Haldimann A; Papp-Wallace KM; Bonomo RA
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182530
[TBL] [Abstract][Full Text] [Related]
7. Role of Double-Carbapenem Regimen in the Treatment of Infections due to Carbapenemase Producing Carbapenem-Resistant
Cancelli F; Oliva A; De Angelis M; Mascellino MT; Mastroianni CM; Vullo V
Biomed Res Int; 2018; 2018():2785696. PubMed ID: 30581848
[TBL] [Abstract][Full Text] [Related]
8. In vitro evaluation of double carbapenem and colistin combinations against OXA-48, NDM carbapenemase-producing colistin-resistant Klebsiella pneumoniae strains.
Erdem F; Abulaila A; Aktas Z; Oncul O
Antimicrob Resist Infect Control; 2020 May; 9(1):70. PubMed ID: 32430058
[TBL] [Abstract][Full Text] [Related]
9. Frequency Determination of Carbapenem-Resistant Klebsiella Pneumoniae (CRKP) Isolated from hospitals in Isfahan of Iran and Evaluation of Synergistic Effect of Colistin and Meropenem on them.
Gheitani L; Fazeli H; Moghim S; Nasr Isfahani B
Cell Mol Biol (Noisy-le-grand); 2018 Jan; 64(1):70-74. PubMed ID: 29412797
[TBL] [Abstract][Full Text] [Related]
10. In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.
Oliva A; Scorzolini L; Cipolla A; Mascellino MT; Cancelli F; Castaldi D; D'Abramo A; D'Agostino C; Russo G; Ciardi MR; Mastroianni CM; Vullo V
J Antimicrob Chemother; 2017 Jul; 72(7):1981-1984. PubMed ID: 28369424
[TBL] [Abstract][Full Text] [Related]
11. In vivo study assessed meropenem and amikacin combination therapy against carbapenem-resistant and carbapenemase-producing Enterobacteriaceae strains.
Hagihara M; Kato H; Yamashita R; Soda M; Watanabe H; Sakanashi D; Shiota A; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Kitaichi K; Mikamo H
J Infect Chemother; 2020 Jan; 26(1):1-7. PubMed ID: 31735629
[TBL] [Abstract][Full Text] [Related]
12. Study of
Zhang W; Guo Y; Yang Y; Dong D; Zheng Y; Zhu D; Hu F
Microb Drug Resist; 2020 Mar; 26(3):204-210. PubMed ID: 31553260
[No Abstract] [Full Text] [Related]
13. Antibacterial activity and carbapenem re-sensitizing ability of 1,10-phenanthroline-5,6-dione and its metal complexes against KPC-producing Klebsiella pneumoniae clinical strains.
Vianez Peregrino I; Ferreira Ventura R; Borghi M; Pinto Schuenck R; Devereux M; McCann M; Souza Dos Santos AL; FerreiraNunes AP
Lett Appl Microbiol; 2021 Aug; 73(2):139-148. PubMed ID: 33843058
[TBL] [Abstract][Full Text] [Related]
14. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
Pournaras S; Vrioni G; Neou E; Dendrinos J; Dimitroulia E; Poulou A; Tsakris A
Int J Antimicrob Agents; 2011 Mar; 37(3):244-7. PubMed ID: 21236643
[TBL] [Abstract][Full Text] [Related]
15. In vitro synergy of β-lactam combinations against KPC-producing Klebsiella pneumoniae strains.
Lawandi A; Leite G; Cheng MP; Lefebvre B; Longtin J; Lee TC
J Antimicrob Chemother; 2019 Dec; 74(12):3515-3520. PubMed ID: 31730163
[TBL] [Abstract][Full Text] [Related]
16. Nitro-Carba test, a novel and simple chromogenic phenotypic method for rapid screening of carbapenemase-producing Enterobacteriaceae.
Teethaisong Y; Nakouti I; Evans K; Eumkeb G; Hobbs G
J Glob Antimicrob Resist; 2019 Sep; 18():22-25. PubMed ID: 30668995
[TBL] [Abstract][Full Text] [Related]
17. The efflux pump inhibitor phenylalanine-arginine β-naphthylamide (PAβN) increases resistance to carbapenems in Chilean clinical isolates of KPC-producing Klebsiella pneumoniae.
Vera-Leiva A; Carrasco-Anabalón S; Lima CA; Villagra N; Domínguez M; Bello-Toledo H; González-Rocha G
J Glob Antimicrob Resist; 2018 Mar; 12():73-76. PubMed ID: 29275225
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of generic meropenem products in combination with colistin in carbapenemase-producing Klebsiella pneumoniae experimental osteomyelitis.
Tattevin P; Dinh A; Ghout I; Mouton W; Verdier MC; Laurent F; Lemaitre F; Gatin L; Saleh-Mghir A; Crémieux AC
Int J Antimicrob Agents; 2020 Nov; 56(5):106152. PubMed ID: 32898684
[TBL] [Abstract][Full Text] [Related]
19. Characterization of porin expression in Klebsiella pneumoniae Carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems.
Hong JH; Clancy CJ; Cheng S; Shields RK; Chen L; Doi Y; Zhao Y; Perlin DS; Kreiswirth BN; Nguyen MH
Antimicrob Agents Chemother; 2013 May; 57(5):2147-53. PubMed ID: 23459476
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network.
Zhang Y; Wang Q; Yin Y; Chen H; Jin L; Gu B; Xie L; Yang C; Ma X; Li H; Li W; Zhang X; Liao K; Man S; Wang S; Wen H; Li B; Guo Z; Tian J; Pei F; Liu L; Zhang L; Zou C; Hu T; Cai J; Yang H; Huang J; Jia X; Huang W; Cao B; Wang H
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
